Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]

Subjects

Subjects :

*THERAPEUTIC use of monoclonal antibodies
*SORAFENIB
*CANCER patients
*HEPATOCELLULAR carcinoma
*TREATMENT effectiveness
*THERAPEUTICS

Details

Language :

English

ISSN :

09598049

Volume :

100

Database :

Academic Search Index

Journal :

European Journal of Cancer

Publication Type :

Academic Journal

Accession number :

130857610

Full Text :

https://doi.org/10.1016/j.ejca.2018.06.002